Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MB07803

Other · developed by Ligand Pharmaceuticals

Phase 2 Most advanced trial (none active)
LGND Developer
1 Registered trials

What is MB07803?

MB07803 is a drug under study in type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
Ligand Pharmaceuticals (LGND)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
GG81XF45C2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00458016 Phase 2 Type 2 Diabetes Mellitus Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type 2 Diabetes Mellitus

More from Ligand Pharmaceuticals

Follow LGND, the company behind MB07803

See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LGND catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.